Other Non-Current Liabilities
Gilead Sciences Other Non-Current Liabilities increased by 3.0% to $1.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.2%, from $1.34B to $1.20B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows relatively stable performance with a -0.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.18B | $962.00M | $976.00M | $944.00M | $988.00M | $1.11B | $1.18B | $1.28B | $1.35B | $924.00M | $1.28B | $1.40B | $1.42B | $1.40B | $1.30B | $1.34B | $1.29B | $1.18B | $1.17B | $1.20B |
| QoQ Change | — | -18.2% | +1.5% | -3.3% | +4.7% | +11.9% | +6.6% | +8.3% | +6.0% | -31.8% | +38.5% | +9.0% | +1.6% | -1.6% | -7.2% | +3.2% | -3.5% | -8.4% | -1.4% | +3.0% |
| YoY Change | — | — | — | — | -16.0% | +15.0% | +20.8% | +35.3% | +37.0% | -16.5% | +8.6% | +9.2% | +4.7% | +51.1% | +1.2% | -4.2% | -9.0% | -15.3% | -10.0% | -10.2% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's other non-current liabilities?
- Gilead Sciences (GILD) reported other non-current liabilities of $1.20B in Q1 2026.
- How has Gilead Sciences's other non-current liabilities changed year-over-year?
- Gilead Sciences's other non-current liabilities decreased by 10.2% year-over-year, from $1.34B to $1.20B.
- What is the long-term trend for Gilead Sciences's other non-current liabilities?
- Over 5 years (2020 to 2025), Gilead Sciences's other non-current liabilities has grown at a -0.8% compound annual growth rate (CAGR), from $1.21B to $1.17B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.